Granted Patent B2

US 12,558,359 · App. 17/916,195 · Granted Feb 24, 2026

Inventors: Stefan Hofmann (Langenfeld, DE); Venkata-Rangarao Kanikanti (Leverkusen, DE); Franziska Schmidt (Duesseldorf, DE); Sandra Mangold-Gehring (Solingen, DE); Annette Boegel (Leichlingen, DE); Brigitte Pommer (Wermelskirchen, DE)

Assignee: Elanco Animal Health GmbH

A61K31/5377A61K9/0053A61K47/10A61K47/12A61K47/14A61K47/44

Abstract

Claims (34)

1 . A method for improving the acceptance or voluntary acceptance of drug intake in an animal comprising administering to the animal a liquid drug-containing formulation comprising:

A) at least one drug, which is a hypoxia-inducible factor prolyl hydroxylase inhibitor,

B) at least one natural oil of herbal origin, and

C) at least one natural oil of animal origin;

wherein the hypoxia-inducible factor prolyl hydroxylase inhibitor is a compound of formula (I)

or a salt, stereoisomer, tautomer, or N-oxide thereof;

wherein the liquid drug-containing formulation is administered to a cat;

wherein the liquid drug-containing formulation is administered to a dog; and

wherein the acceptance or voluntary acceptance of drug intake is improved over an administration period of at least two weeks.

2 . The method of claim 1 , wherein the at least one natural oil of herbal origin is almond oil, apricot kernel oil, canola oil, castor oil, coconut oil, cottonseed oil, flaxseed oil, grape oil, hemp oil, maize oil, olive oil, palm oil, peanut oil, sesame seed oil, soya oil, sunflower oil, thistle oil, rapeseed oil, rice bran oil, or wheat germ oil.

3 . The method of claim 1 , wherein the at least one natural oil of herbal origin is modified almond oil, modified apricot kernel oil, modified canola oil, modified castor oil, modified coconut oil, modified cottonseed oil, modified flaxseed oil, modified grape oil, modified hemp oil, modified maize oil, modified olive oil, modified palm oil, modified peanut oil, modified sesame seed oil, modified soya oil, modified sunflower oil, modified thistle oil, modified rapeseed oil, modified rice bran oil, or modified wheat germ oil, and

wherein the modification is alcoholysis.

4 . The method of claim 1 , wherein the at least one natural oil of animal origin, is fish oil, optionally salmon oil.

5 . The method of claim 1 , wherein the formulation further comprises a thickener.

6 . The method of claim 1 , wherein the liquid drug-containing formulation further comprises

at least one antioxidant, wherein the antioxidant is ascorbyl palmitate, butylhydroxytoluene, butylhydroxyanisole, citric acid, lecithins, propyl gallate, tocopherol, or a combination thereof; and/or

at least one preservative, wherein the preservative is ethanol, propylene glycol, butanol, chlorobutanol, benzoic acid, sorbic acid, para-hydroxybenzoic esters, or a combination thereof; and

optionally at least one surfactant.

7 . The method of claim 1 , wherein the at least one natural oil of herbal origin is soya oil or sunflower oil and wherein at least one natural oil of animal origin is fish oil.

8 . The method of claim 1 , wherein the at least one natural oil of herbal origin is modified maize oil.

9 . The method of claim 5 , wherein the thickener is glycerol dibehenate.

10 . The method of claim 5 , wherein the thickener is glycerol ester.

11 . The method of claim 5 , wherein the glycerol ester is a glycerol ester with C 12 -C 24 fatty acids or is a monoester, a diester, a triester, or is a mixture thereof.

12 . The method of claim 1 , wherein the liquid drug-containing formulation further comprises

E) at least one antioxidant selected from the group consisting of ascorbyl palmitate, butylhydroxytoluene, butylhydroxyanisole, citric acid, lecithins, propyl gallate, tocopherol, and combinations of these antioxidants; and/or

F) at least one preservative selected from the group consisting of ethanol, propylene glycol, butanol, chlorobutanol, benzoic acid, sorbic acid, para-hydroxybenzoic esters, and combinations thereof; and/or

G) optionally at least one surfactant.

13 . The method of claim 1 , wherein the liquid drug-containing formulation comprises

A) the hypoxia-inducible factor prolyl hydroxylase inhibitor in an amount of from 0.1 to 20 wt.-%, optionally from 0.5 to 10 wt.-%, based on the total weight of the liquid drug-containing formulation,

B) the at least one natural oil of herbal origin in an amount of from 50 to 99.8 wt.-%, optionally from 70 to 98.97 wt.-%, based on the total weight of the liquid drug-containing formulation,

C) optionally the at least one natural oil of animal origin in an amount of from 0.01 to 5 wt.-%, optionally from 0.01 to 1.5 wt.-%, based on the total weight of the liquid drug-containing formulation,

D) optionally the at least one thickener in an amount of from 0.1 to 10 wt.-%, optionally from 0.5 to 5 wt.-%, based on the total weight of the liquid drug-containing formulation,

E) optionally at least one antioxidant in an amount of from 0.01 to 2 wt.-%, optionally from 0.01 to 1.5 wt.-%, based on the total weight of the liquid drug-containing formulation, and

F) optionally at least one preservative in an amount of from 0.01 to 2 wt.-%, optionally from 0.01 to 1.5 wt.-%, based on the total weight of the liquid drug-containing formulation.

Assignments (2)

Priority Claims (1)

Continuity (1)

References Cited (40)